A Study in Healthy Men to Test How Zongertinib is Taken up in the Body When Taken With or Without Food

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 19, 2023

Primary Completion Date

January 2, 2024

Study Completion Date

January 2, 2024

Conditions
Healthy
Interventions
DRUG

zongertinib

Participants received a single oral dose of 240 mg Zongertinib (4 x 60 mg tablets) in two periods: in Period 1 after an overnight fast of at least 10 hours, and in Period 2 following a high fat/high calorie meal.

Trial Locations (1)

13627

CRS Clinical Research Services Berlin GmbH, Berlin

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY